When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...

Eli Lilly (NYSE: LLY) stock was the picture of health on Friday. Shares of the massive American pharmaceutical company rose ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.

Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...

He also maintained his $977 per-share price target ... it's the well-capitalized Eli Lilly. I would even consider it to be a leading healthcare stock appropriate for any portfolio at this point.

Eli Lilly and Company (NYSE ... However, InvestingPro's Fair Value analysis suggests the stock may be trading above its intrinsic value, warranting careful consideration by investors.

Eli Lilly is a stock which you might consider to be "priced ... Even now, with the dip in value, its price-to-earnings (P/E) multiple is close to 80, which still isn't terribly cheap.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...

Citi analyst Geoff Meacham maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today. The company’s shares closed last Friday ...